China custom Synthesis market have a great value
Charles River, the US $1.6 billion acquisition of Wuxi Pharmaceutical Wuxi, has been a powerful event in China’s custom synthesis CRO industry. The event, led by a large US company with global influence, reflects in another way the value and development prospects of China’s custom-made synthetic CRO market.
The drug Wuxi is also the winner in the country’s biggest drug-cross-border takeover so far, possibly the world’s largest research and development company. In the peak period of enterprise development rather than recession, to achieve the original capital of the high price exit, is a lot of entrepreneurs, PE in the investment before the road map has been designed. As a 10-year-old start-up, $1.6 billion was sold at a high price. Investors get rich returns from the deal, and drug Wuxi can take this stride into the United States and other developed countries such as the new drug research and development market, dabbling in the field is rich, development prospects to broaden, the future is limitless.
So, in addition to the happy party, who is worried about this, who is the regret and even lost it? The former is naturally those with more research and development outsourcing needs of pharmaceutical enterprises, with more and more CRO mergers and acquisitions, the field of industry concentration will significantly improve, of which the “Big Mac” discourse rights significantly strengthened, research and development outsourcing of the order price must rise. And the latter is the industry for the rise of Chinese pharmaceutical companies have high hopes for insight, in experts, drug Wuxi is the most potential to become the world-class domestic drug enterprises, now already living in the top of the CRO, and the global CRO industry is not an absolute giant enterprise, Charles, Corvins and other large companies in the United States market share of only 10%.
The merger of China’s big CRO companies with an international giant has created a bellwether in the industry, which will undoubtedly change the distribution of the Chinese medicine industry and the world’s custom synthetic CRO domain. It is almost certain that more and more of the CRO industry is facing shuffling, and the development of China’s CRO is accelerating. Another big value and effect of the incident is that the domestic CRO enterprise focused on development and reform, while seriously thinking of the big international companies to buy and merge the bright future.http://www.haihengpharma.com/china-custom-synthesis-market-have-a-great-value/News
Charles River, the US $1.6 billion acquisition of Wuxi Pharmaceutical Wuxi, has been a powerful event in China's custom synthesis CRO industry. The event, led by a large US company with global influence, reflects in another way the value and development prospects of China's custom-made synthetic CRO market. The drug Wuxi...firstname.lastname@example.orgAdministratorJiangsu Haiheng Pharmaceutical Co.,Ltd.